Choong Ang Vaccine Laboratory Co. Ltd - Asset Resilience Ratio
Choong Ang Vaccine Laboratory Co. Ltd (072020) has an Asset Resilience Ratio of 9.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Choong Ang Vaccine Laboratory Co. Ltd's Asset Resilience Ratio has changed over time. Check 072020 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Choong Ang Vaccine Laboratory Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Choong Ang Vaccine Laboratory Co. Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.01 Billion | 9.65% |
| Total Liquid Assets | ₩12.01 Billion | 9.65% |
Asset Resilience Insights
- Limited Liquidity: Choong Ang Vaccine Laboratory Co. Ltd maintains only 9.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Choong Ang Vaccine Laboratory Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Choong Ang Vaccine Laboratory Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Choong Ang Vaccine Laboratory Co. Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Choong Ang Vaccine Laboratory Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.21% | ₩13.77 Billion ≈ $9.33 Million |
₩122.82 Billion ≈ $83.23 Million |
-12.44pp |
| 2024-12-31 | 23.65% | ₩29.15 Billion ≈ $19.76 Million |
₩123.28 Billion ≈ $83.54 Million |
+0.72pp |
| 2023-12-31 | 22.93% | ₩27.42 Billion ≈ $18.58 Million |
₩119.59 Billion ≈ $81.05 Million |
+7.27pp |
| 2022-12-31 | 15.66% | ₩17.98 Billion ≈ $12.19 Million |
₩114.86 Billion ≈ $77.84 Million |
-3.35pp |
| 2021-12-31 | 19.00% | ₩21.47 Billion ≈ $14.55 Million |
₩112.95 Billion ≈ $76.55 Million |
-2.68pp |
| 2020-12-31 | 21.69% | ₩22.77 Billion ≈ $15.43 Million |
₩104.98 Billion ≈ $71.14 Million |
+0.22pp |
| 2019-12-31 | 21.47% | ₩20.73 Billion ≈ $14.05 Million |
₩96.57 Billion ≈ $65.44 Million |
-3.62pp |
| 2018-12-31 | 25.09% | ₩24.27 Billion ≈ $16.45 Million |
₩96.74 Billion ≈ $65.56 Million |
+6.69pp |
| 2017-12-31 | 18.40% | ₩15.02 Billion ≈ $10.18 Million |
₩81.62 Billion ≈ $55.32 Million |
-8.91pp |
| 2016-12-31 | 27.31% | ₩20.09 Billion ≈ $13.61 Million |
₩73.54 Billion ≈ $49.84 Million |
+19.11pp |
| 2015-12-31 | 8.21% | ₩5.10 Billion ≈ $3.45 Million |
₩62.10 Billion ≈ $42.09 Million |
+2.19pp |
| 2014-12-31 | 6.02% | ₩3.65 Billion ≈ $2.47 Million |
₩60.60 Billion ≈ $41.07 Million |
-- |
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Ko… Read more